Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M5XJ
|
|||
| Drug Name |
DCC-3014
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 1 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | ||
| Company |
Deciphera Pharmaceuticals Waltham, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Macrophage colony-stimulating factor 1 receptor (CSF1R) | Target Info | Inhibitor | [1] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| Viral protein interaction with cytokine and cytokine receptor | ||||
| PI3K-Akt signaling pathway | ||||
| Osteoclast differentiation | ||||
| Hematopoietic cell lineage | ||||
| Pathways in cancer | ||||
| Transcriptional misregulation in cancer | ||||
| Acute myeloid leukemia | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.